Announced Date: 2025-10-21 (October 21, 2025)<\/p>\n\n\n\n
Asset Name: IBI363 (PD-1\/IL-2\u03b1-bias), IBI343 (CLDN18.2 ADC)\uff0cIBI3001 (EGFR\/B7H3 ADC)<\/p>\n\n\n\n
Licensor (Seller): Innovent Biologics (China)<\/p>\n\n\n\n
Licensee (Buyer): Takada<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset 1: IBI363 (PD-1\/IL-2\u03b1-bias)<\/p>\n\n\n\n
Asset Modality: bispecific antibody fusion protein<\/p>\n\n\n\n
Asset Target: PD-1, IL-2\u00a0<\/p>\n\n\n\n
Potential Indication: several solid tumor types, including non-small cell lung and colorectal cancers<\/p>\n\n\n\n
Current Stage: globally Phase 1\/2 and Phase 2 clinical trials<\/p>\n\n\n\n
.<\/p>\n\n\n\n
IBI363 Co-develop Terms: <\/p>\n\n\n\n
Takeda and Innovent will co-develop IBI363 globally with a 60\/40 (Takeda\/Innovent) cost split and co-commercialize it in the U.S. with a 60\/40 (Takeda\/Innovent) profit or loss split. <\/p>\n\n\n\n
Takeda will lead co-commercialization efforts in the U.S. and will have the exclusive right to commercialize IBI363 outside of the U.S. and Greater China. <\/p>\n\n\n\n
Takeda will have global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset 2: IBI343 (CLDN18.2 ADC)<\/p>\n\n\n\n
Asset Modality: antibody-drug conjugate (ADC)<\/p>\n\n\n\n
Asset Target: Claudin 18.2 protein<\/p>\n\n\n\n
Potential Indication: gastric and pancreatic cancers<\/p>\n\n\n\n
Current Stage: Phase 3 clinical trial in previously treated gastric cancer in Japan and China, completed a global Phase 1\/2 trial in previously treated pancreatic cancer.\u00a0<\/p>\n\n\n\n
Takeda will develop, manufacture and commercialize IBI343 worldwide, outside of Greater China.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset 3: IBI3001 (EGFR\/B7H3 ADC)<\/p>\n\n\n\n
Asset Modality: bispecific ADC<\/p>\n\n\n\n
Asset Target: EGFR and B7H3<\/p>\n\n\n\n
Potential Indication: solid tumors<\/p>\n\n\n\n
Current Stage: Phase 1 clinical trial in patients with locally advanced or metastatic solid tumors in the U.S., China and Australia.<\/p>\n\n\n\n
Takeda will receive an exclusive option to license global rights outside of Greater China for IBI3001.<\/p>\n\n\n\n
Innovent will be solely responsible for clinical development of IBI3001 prior to potential exercise of the option to license.\u00a0<\/p>\n\n\n\n
.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Payment Detail:<\/p>\n\n\n\n
Innovent will receive US$1.2 billion upfront payment upon closing of the transaction, which includes an equity investment of US$100 million in Innovent by Takeda. The upfront payment will be funded through cash on hand. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
Innovent will also be eligible for potential milestones and royalty payments (up to US$10.2 billion) , and a profit or loss split 60\/40 (Takeda\/Innovent) solely with respect to IBI363 in the U.S., where Takeda will lead the commercialization effort while Innovent will have a co-commercialization right. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
If Takeda exercises the option for IBI3001, Innovent will be eligible for an option exercise fee and additional potential milestone and royalty payments. <\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n